Skip to main content
. 2019 Jun 20;104(10):4347–4355. doi: 10.1210/jc.2019-00828

Table 2.

Psychometric and Behavioral Measures

Testosterone Placebo P Valuea
Pretreatment 24 wk Pretreatment 24 wk
Depression and anxiety symptom severity
 HAM-D scoreb 15.2 ± 3.6 13.1 ± 5.5 15.5 ± 4.9 12.0 ± 6.0 0.72
 HAM-A scorec 14.8 ± 5.5 10.8 ± 4.9 15.1 ± 5.3 10.8 ± 5.0 0.25
Eating disorder symptoms/behaviors
 Vomiting over last 4 wk, number of episodes 6 ± 18 7 ± 21 3 ± 7 3 ± 7 0.83
 Overexercise over last 4 wk, number of episodes 6 ± 9 3 ± 6 5 ± 8 5 ± 8 0.05
 EDE-Q global score 3.1 ± 1.3 2.9 ± 1.5 3.3 ± 1.3 2.8 ± 1.2 0.93
 EQE-Q subscales
  Dietary restraint 3.0 ± 1.7 2.7 ± 2.0 3.0 ± 1.5 2.7 ± 1.4 0.63
  Eating concern 2.5 ± 1.5 2.3 ± 1.5 2.7 ± 1.4 2.3 ± 1.4 0.57
  Weight concern 3.2 ± 1.5 3.0 ± 1.6 3.6 ± 1.5 3.0 ± 1.5 0.90
  Shape concern 3.8 ± 1.4 3.5 ± 1.7 3.9 ± 1.5 3.3 ± 1.4 0.93
 EDI-2 subscales
  Drive for thinness 9.8 ± 6.3 9.3 ± 6.8 11.1 ± 6.8 9.6 ± 6.7 0.89
  Bulimia 2.8 ± 4.6 1.8 ± 2.7 4 0.0 ± 5.8 2.6 ± 4.8 0.58
  Body dissatisfaction 12.5 ± 7.1 10.6 ± 7.8 10.9 ± 6.5 10.0 ± 7.0 0.32
  Ineffectiveness 7.8 ± 6.4 8.2 ± 7.0 9.1 ± 6.1 7.2 ± 5.7 0.52
  Perfectionism 9.1 ± 4.8 7.1 ± 3.9 9.1 ± 5.2 8.4 ± 5.3 0.54
  Interpersonal distrust 4.8 ± 3.7 3.8 ± 3.7 5.4 ± 4.1 4.4 ± 3.9 0.70
  Interoceptive awareness 7.8 ± 5.9 6.0 ± 5.6 9.8 ± 6.9 7.9 ± 6.3 0.99
  Maturity fears 5.4 ± 5.8 5.0 ± 5.6 5.6 ± 4.3 2.7 ± 3.2 0.22
  Asceticism 6.7 ± 4.7 5.7 ± 4.7 8.5 ± 6.0 8.0 ± 6.4 0.84
  Impulse regulation 4.3 ± 4.8 3.1 ± 4.8 5.7 ± 5.5 4.3 ± 5.2 0.75
  Social insecurity 6.5 ± 4.3 6.4 ± 4.6 7.6 ± 4.3 6.1 ± 4.0 0.11
BPAQd
 Physical aggression 18.9 ± 8.7 17.8 ± 6.4 17.4 ± 4.9 17.3 ± 4.3 0.21
 Verbal aggression 13.3 ± 5.4 12.5 ± 5.1 15.3 ± 5.1 14.2 ± 4.9 0.45
 Anger 18.5 ± 7.3 17.3 ± 4.7 19.8 ± 7.3 19.2 ± 6.2 0.04
 Hostility 24.1 ± 11.2 23.5 ± 10.6 24.2 ± 11.4 21.5 ± 9.7 0.40

For all scales/questionnaires, higher scores indicate worse symptom severity. Data are mean ± SD.

a

P value for comparison of change in psychometric or behavioral measure over 24 wk in subjects randomized to receive testosterone vs placebo.

b

HAM-D: 0–7, not depressed; 8–13, mild depression; 14–18, moderate depression; 19–22, severe depression; ≥23, very severe depression.

c

HAM-A: 0–17, mild anxiety; 18–24, moderate anxiety; ≥25, severe anxiety.

d

Performed as part of safety evaluation.